
|Videos|October 16, 2017
APX001: A New Antifungal with Activity Against Candida auris
Author(s)Contagion® Editorial Staff
Ciara Kennedy, PhD, breaks down APX001, a new antifungal with a unique mechanism of action.
Advertisement
Ciara Kennedy, PhD, president and CEO of Amplyx Pharmaceuticals, Inc, explains that by targeting an enzyme with the fungal cell, APX001 is able to inhibit the formation of the fungal cell wall, thereby decreasing the virulence, pathogenicity, and biofilm-producing capabilities of the fungus. Data from phase 1 studies are promising for this new antifungal to be able to be administered in both intravenous and oral forms, providing physicians with a new opportunity for continuum of care, using the same mechanism of action.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Reductions in Funding, Personnel Will Leave US Less Prepared for Future Infectious Disease Outbreaks
2
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311
3
ASM Initiative Aims to Advance Phage Therapy for Drug-Resistant Infections
4
Challenges to Adopting New Therapeutics: Familiarity, Diagnostics, and Real-World Use in Persistent Bacteremia
5









































































































































































